$ASPN

B.Riley reiterates Buy on Aspen Aerogels stock, $9 target

B.Riley reiterated a Buy rating and $9.00 price target on Aspen Aerogels (ASPN) after management meetings. The stock is up 107% YTD but may be overvalued. ASPN expects EV production to match sales, strong European EV penetration, and positive adjusted EBITDA by Q3 2026. Q2 2026 revenue beat expectations, but earnings missed.

Original reporting
Published Oct 7, 2026, 9:42 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 7, 2026, 9:52 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$ASPN
Bullish
medium confidence
Mentioned
$ASPN
Relevance
4/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$ASPNBullishLow
01

Why it matters

The analyst's higher price target could spark short‑term buying interest, though the underlying fundamentals remain unchanged.

02

Market read

A modest catalyst for a small‑cap stock; limited broader market impact.

03

What to watch

Potential supply‑chain constraints in EV battery materials could temper growth expectations.

Relevance 4/10Novelty 2/10Timing: none

Background

Aspen Aerogels reported Q2 2026 results with revenue beating estimates but an adjusted loss per share missing expectations. The analyst reiterates coverage after recent management meetings.

Company-level read

Ticker impact

$ASPNBullishMedium confidence
Context

Analyst B.Riley reiterated a Buy rating and a $9 price target for Aspen Aerogels, citing recent management meetings and Q2 results.

Expected impact

likely upward pressure as investors consider the higher target

Evidence & confidence

The rating upgrade and higher target provide a fresh catalyst, but the underlying earnings data are already public, limiting impact.

Market effects

May reinforce positive sentiment in the advanced materials and EV battery storage sector.

Limited to U.S. investors focused on small-cap industrials.

Low, as the story is company‑specific.

Counterpoint

The price target may be overly optimistic given the modest earnings beat and lingering loss per share.

Key entities

  • B.Riley

    Equity analyst who reaffirmed a Buy rating and set a $9 target.

  • Aspen Aerogels

    Manufacturer of advanced aerogel insulation products.

Related articles

$ASPNMed

Aspen Aerogels Q2 Earnings Call Highlights

Aspen Aerogels (ASPN) reported Q2 gross profit of $3.3M (7% margin) after $5.3M of incremental costs tied to an April explosion at its East Providence plant. Adjusted gross profit was $8.6M (17%). GAAP net loss was $23.3M. The company is restarting the plant and expects full capacity in 1H 2027, while raising 2026 European Thermal Barrier revenue outlook to $20M-$30M.

$ASPNHigh

Aspen Aerogels, Inc. Reports Second Quarter 2026 Financial Results and Recent

ASPEN AEROGELS INC (ASPN) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 Aspen Aerogels, Inc. Reports Second Quarter 2026 Financial Results and Recent Business Highlights Q2 2026 Thermal Barrier revenue of $29.5 million, up 81% quarter-over-quarter Q3 2026 expected revenue range of $65 to $80 million and adjusted EBITDA range of $7 to $15

$ASPNMed

Beerenberg Prevails in Patent Case Against Aspen Aerogels

South Korea’s Patent Court invalidated three Aspen Aerogels patents covering improved hydrophobic aerogel material, according to the company’s press release. The ruling upheld the Intellectual Property Trial and Appeal Board’s view that the patents failed patentability requirements. Beerenberg, an insulation-products firm, said the decision removes uncertainty over infringement claims.

$SLBMedAI 8/10

SLB Ltd (SLB) Q3 2026 Earnings Call Highlights: Broad-Based Growth, Margin Expansion

SLB Ltd (SLB) reported Q3 2026 earnings, highlighting broad-based growth and margin expansion. Middle East revenue remains uncertain due to geopolitics, with Q4 expected at $1.9B, 83% of Q4 2025. The company recorded a $187M non-cash pension charge. Digital sales declined sequentially, and pricing pressure impacts margins. Free cash flow in Q4 depends on collections. CEO Le Peuch expects mid-single-digit global activity growth in 2027, with SLB outperforming.